Free Trial

Enzon Pharmaceuticals (ENZN) 10K Form and Latest SEC Filings 2026

Enzon Pharmaceuticals logo
$5.65 -0.11 (-1.91%)
As of 09:38 AM Eastern

Latest Enzon Pharmaceuticals SEC Filings & Recent Activity

Enzon Pharmaceuticals (OTCMKTS:ENZN) has submitted 144+ documents to the U.S. Securities and Exchange Commission (SEC) since 2018. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form 10-Q submitted on May 4, 2026.

Form 4
Viskase Holdings, Inc. Reports Ownership Change on Mar. 27, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Enzon Pharmaceuticals Files Current Report on Apr. 21, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
Enzon Pharmaceuticals Files Quarterly Report on May. 4, 2026

The 10-Q contains Enzon Pharmaceuticals's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

Enzon Pharmaceuticals SEC Filing History

Browse Enzon Pharmaceuticals' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/04/2026 3:16 PM
Enzon Pharmaceuticals (727510) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/01/2026 7:56 AM
Pettit Craig (2132862) Reporting
Enzon Pharmaceuticals (727510) Issuer
Form 3
Initial statement of beneficial ownership of securities  
04/21/2026 3:38 PM
Enzon Pharmaceuticals (727510) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/16/2026 3:36 PM
Enzon Pharmaceuticals (727510) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/15/2026 3:17 PM
Enzon Pharmaceuticals (727510) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/27/2026 6:48 PM
ICAHN CARL C (921669) Filed by
Enzon Pharmaceuticals (727510) Subject
Form SCHEDULE 13D/A
03/27/2026 6:50 PM
ICAHN CARL C (921669) Reporting
ICAHN ENTERPRISES G.P. INC. (1257324) Reporting
ICAHN ENTERPRISES HOLDINGS L.P. (1034563) Reporting
Enzon Pharmaceuticals (727510) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/26/2026 7:20 PM
Shea Kenneth (1563012) Reporting
Enzon Pharmaceuticals (727510) Issuer
Form 3
Initial statement of beneficial ownership of securities  
03/26/2026 7:21 PM
King Joseph D (2117277) Reporting
Enzon Pharmaceuticals (727510) Issuer
Form 3
Initial statement of beneficial ownership of securities  
03/26/2026 7:10 PM
Plescia John (2117263) Reporting
Enzon Pharmaceuticals (727510) Issuer
Form 3
Initial statement of beneficial ownership of securities  
03/26/2026 7:11 PM
Stender Mackenzie (2117312) Reporting
Enzon Pharmaceuticals (727510) Issuer
Form 3
Initial statement of beneficial ownership of securities  
03/26/2026 7:12 PM
Schouten Robert (2117335) Reporting
Enzon Pharmaceuticals (727510) Issuer
Form 3
Initial statement of beneficial ownership of securities  
03/26/2026 7:13 PM
Stevens Jan (2117245) Reporting
Enzon Pharmaceuticals (727510) Issuer
Form 3
Initial statement of beneficial ownership of securities  
03/26/2026 7:14 PM
Blecic Michael (2117332) Reporting
Enzon Pharmaceuticals (727510) Issuer
Form 3
Initial statement of beneficial ownership of securities  
03/26/2026 7:15 PM
Davis Thomas Dale (1664137) Reporting
Enzon Pharmaceuticals (727510) Issuer
Form 3
Initial statement of beneficial ownership of securities  
03/26/2026 7:16 PM
DeMaria Dustin (2016650) Reporting
Enzon Pharmaceuticals (727510) Issuer
Form 3
Initial statement of beneficial ownership of securities  
03/26/2026 7:17 PM
Flint Robert (2005770) Reporting
Enzon Pharmaceuticals (727510) Issuer
Form 3
Initial statement of beneficial ownership of securities  
03/26/2026 7:19 PM
Herrera Armando Jr. (2117236) Reporting
Enzon Pharmaceuticals (727510) Issuer
Form 3
Initial statement of beneficial ownership of securities  
03/26/2026 7:08 PM
Kwak Colin Nicholas (2063917) Reporting
Enzon Pharmaceuticals (727510) Issuer
Form 3
Initial statement of beneficial ownership of securities  
03/26/2026 7:09 PM
SHEA PETER (1384393) Reporting
Enzon Pharmaceuticals (727510) Issuer
Form 3
Initial statement of beneficial ownership of securities  
03/26/2026 4:24 PM
Enzon Pharmaceuticals (727510) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/25/2026 7:33 AM
Enzon Pharmaceuticals (727510) Subject
Form SC TO-I/A
03/25/2026 7:36 AM
Enzon Pharmaceuticals (727510) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/25/2026 7:38 AM
Enzon Pharmaceuticals (727510) Subject
Form 425
03/24/2026 7:33 AM
Enzon Pharmaceuticals (727510) Filer
Form 8-A12G/A
03/24/2026 7:35 AM
Enzon Pharmaceuticals (727510) Subject
Form SC TO-I/A
03/24/2026 7:30 AM
Enzon Pharmaceuticals (727510) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/24/2026 7:30 AM
Enzon Pharmaceuticals (727510) Subject
Form 425
03/19/2026 3:16 PM
Enzon Pharmaceuticals (727510) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/19/2026 3:07 PM
Enzon Pharmaceuticals (727510) Subject
Form SC TO-I/A
03/18/2026 7:45 AM
Enzon Pharmaceuticals (727510) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/16/2026 3:10 PM
Enzon Pharmaceuticals (727510) Subject
Form 425
03/16/2026 3:00 PM
Enzon Pharmaceuticals (727510) Subject
Form SC TO-I/A
03/11/2026 7:31 AM
Enzon Pharmaceuticals (727510) Subject
Form SC TO-I/A
03/11/2026 7:34 AM
Enzon Pharmaceuticals (727510) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/11/2026 7:36 AM
Enzon Pharmaceuticals (727510) Subject
Form 425
03/11/2026 7:39 AM
Enzon Pharmaceuticals (727510) Filer
Form 8-A12G/A
03/09/2026 3:09 PM
Enzon Pharmaceuticals (727510) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/09/2026 3:13 PM
Enzon Pharmaceuticals (727510) Subject
Form 425
02/27/2026 7:37 AM
Enzon Pharmaceuticals (727510) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/27/2026 7:39 AM
Enzon Pharmaceuticals (727510) Subject
Form 425
02/27/2026 7:43 AM
Enzon Pharmaceuticals (727510) Filer
Form 8-A12G/A
02/27/2026 7:30 AM
Enzon Pharmaceuticals (727510) Subject
Form SC TO-I/A
02/26/2026 3:05 PM
Enzon Pharmaceuticals (727510) Subject
Form SC 14F1
02/11/2026 4:17 PM
Enzon Pharmaceuticals (727510) Subject
Form 425
02/11/2026 4:23 PM
Enzon Pharmaceuticals (727510) Subject
Form SC TO-I/A
02/11/2026 4:14 PM
Enzon Pharmaceuticals (727510) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/01/2026 11:15 PM
Enzon Pharmaceuticals (727510) Filer
Form EFFECT
01/30/2026 5:02 PM
Enzon Pharmaceuticals (727510) Subject
ICAHN CARL C (921669) Filed by
Form SCHEDULE 13D/A
01/30/2026 3:52 PM
Enzon Pharmaceuticals (727510) Subject
Form SC TO-I
01/30/2026 2:13 PM
Enzon Pharmaceuticals (727510) Filer
Form S-4/A
01/30/2026 7:42 AM
Enzon Pharmaceuticals (727510) Filer
Form 8-A12G/A
01/30/2026 7:20 AM
Enzon Pharmaceuticals (727510) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/23/2025 3:50 PM
Enzon Pharmaceuticals (727510) Filer
Form 8-A12G/A
12/23/2025 3:45 PM
Enzon Pharmaceuticals (727510) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/24/2025 3:14 PM
Enzon Pharmaceuticals (727510) Subject
ICAHN CARL C (921669) Filed by
Form SCHEDULE 13D/A
10/24/2025 3:01 PM
Enzon Pharmaceuticals (727510) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/24/2025 3:04 PM
Enzon Pharmaceuticals (727510) Subject
Form 425
09/30/2025 3:45 PM
Enzon Pharmaceuticals (727510) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/30/2025 3:47 PM
Enzon Pharmaceuticals (727510) Filer
Form 8-A12G/A
06/23/2025 7:19 AM
Enzon Pharmaceuticals (727510) Subject
ICAHN CARL C (921669) Filed by
Form SCHEDULE 13D/A
06/23/2025 5:07 AM
Enzon Pharmaceuticals (727510) Subject
Form 425
06/23/2025 5:06 AM
Enzon Pharmaceuticals (727510) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)

Enzon Pharmaceuticals SEC Filings - Frequently Asked Questions

Enzon Pharmaceuticals (ENZN) has submitted 144+ filings to the SEC since 2018. You can browse the complete history or filter by form type using the tools above.

Enzon Pharmaceuticals's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results.

The most recent filing was a Form 10-Q submitted on May 4, 2026. This was a quarterly financial update for 2025.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (OTCMKTS:ENZN) was last updated on 5/6/2026 by MarketBeat.com Staff.
From Our Partners